Invention Grant
- Patent Title: Crystal form of 3-(4-methyl-1h-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride and use thereof
-
Application No.: US17046575Application Date: 2019-04-08
-
Publication No.: US11414388B2Publication Date: 2022-08-16
- Inventor: Deliang Niu , Bojun Ma , Zhanqun Zhu , Qiang Wan
- Applicant: ARIZEST (SHANGHAI) PHARMATECH CO., LTD. , JIANGSU XIDI PHARMACEUTICALS CO., LTD. , SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP CO., LTD.
- Applicant Address: CN Shanghai; CN Jiangsu; CN Shanghai
- Assignee: ARIZEST (SHANGHAI) PHARMATECH CO., LTD.,JIANGSU XIDI PHARMACEUTICALS CO., LTD.,SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP CO., LTD.
- Current Assignee: ARIZEST (SHANGHAI) PHARMATECH CO., LTD.,JIANGSU XIDI PHARMACEUTICALS CO., LTD.,SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP CO., LTD.
- Current Assignee Address: CN Shanghai; CN Jiangsu; CN Shanghai
- Agency: Ice Miller LLP
- Priority: CN201810316286.2 20180410
- International Application: PCT/CN2019/081771 WO 20190408
- International Announcement: WO2019/196802 WO 20191017
- Main IPC: C07D233/00
- IPC: C07D233/00 ; C07D401/14 ; C07D233/58

Abstract:
The present invention relates to a crystal form of 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride and the use thereof. Specifically, disclosed are a crystal form A of a monohydrochloride anhydrous substance of 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride, a method for preparing the crystal form A and the use of the crystal form in the synthesis of nilotinib. The crystal form A of the present invention has good stability and purity, and can be directly used in the preparation and production of nilotinib. The method for preparing nilotinib in the present invention is easy to operate and has high industrial application value.
Public/Granted literature
- US20210139433A1 CRYSTAL FORM OF 3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYLANILINE MONOHYDROCHLORIDE AND USE THEREOF Public/Granted day:2021-05-13
Information query